TherapeuticsMD (NASDAQ: TXMD) is one of 20 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare TherapeuticsMD to similar businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.
This is a summary of current recommendations and price targets for TherapeuticsMD and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TherapeuticsMD currently has a consensus price target of $15.25, indicating a potential upside of 168.96%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.10%. Given TherapeuticsMD’s stronger consensus rating and higher probable upside, equities analysts clearly believe TherapeuticsMD is more favorable than its competitors.
Institutional and Insider Ownership
71.4% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 67.1% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 23.9% of TherapeuticsMD shares are owned by insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares TherapeuticsMD and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares TherapeuticsMD and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|TherapeuticsMD||$19.36 million||-$89.87 million||-14.17|
|TherapeuticsMD Competitors||$3.02 billion||$642.98 million||-23.28|
TherapeuticsMD’s competitors have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
TherapeuticsMD has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, TherapeuticsMD’s competitors have a beta of 1.22, meaning that their average share price is 22% more volatile than the S&P 500.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.